Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

FUSION PHARMACEUTICALS INC.

(FUSN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
09/15/2021 09/16/2021 09/17/2021 09/20/2021 09/21/2021 Date
9.19(c) 8.94(c) 8.98(c) 8.56(c) 8.56(c) Last
39 381 23 631 18 497 38 706 71 461 Volume
+2.11% -2.72% +0.45% -4.68% 0.00% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 45,2 M - -
Net income 2021 -102 M - -
Net cash position 2021 312 M - -
P/E ratio 2021 -3,75x
Yield 2021 -
Sales 2022 4,50 M - -
Net income 2022 -120 M - -
Net cash position 2022 218 M - -
P/E ratio 2022 -3,37x
Yield 2022 -
Capitalization 368 M 368 M -
EV / Sales 2021 1,25x
EV / Sales 2022 33,3x
Nbr of Employees 65
Free-Float 78,2%
More Financials
Company
Fusion Pharmaceuticals Inc. is a clinical-stage oncology company. The Company is focused on developing radiopharmaceuticals as precision medicines. The Company has developed its Targeted Alpha Therapies (TAT) platform together with its Fast-Clear linker technology. Its technology enables it to connect alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the... 
More about the company
Ratings of Fusion Pharmaceuticals Inc.
Trading Rating : 
Investor Rating :  -
ESG Refinitiv : 
-
More Ratings
All news about FUSION PHARMACEUTICALS INC.
09/21FUSION PHARMACEUTICALS : Appoints Eric S. Hoffman, Ph.D. as Senior Vice President, Busines..
PR
09/21FUSION PHARMACEUTICALS : Appoints Eric S. Hoffman, Ph.D. as Senior Vice President, Busines..
AQ
09/02FUSION PHARMACEUTICALS : to Participate in Upcoming Investor Conferences
PR
08/31FUSION PHARMACEUTICALS : Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
PR
08/26FUSION PHARMACEUTICALS : B. Riley Starts Fusion Pharmaceuticals at Buy with $17 PT, Notes ..
MT
08/18FUSION PHARMACEUTICALS : Morgan Stanley Adjusts Price Target on Fusion Pharmaceuticals to ..
MT
08/13Fusion Pharmaceuticals Inc. and TRIUMF Announce Expanded R&D Collaboration for Actinium..
CI
08/13FUSION PHARMACEUTICALS INC. : Entry into a Material Definitive Agreement, Regulation FD Di..
AQ
08/13FUSION PHARMACEUTICALS : Expands Agreement With Triumf for Actinium Supply Production
MT
08/12FUSION PHARMACEUTICALS : and TRIUMF Announce Expanded R&D Collaboration for Actinium Suppl..
PR
08/12Fusion Pharmaceuticals and Triumf Announce Expanded R&D Collaboration for Actinium Supp..
CI
08/11WALL STREET STOCK EXCHANGE : The Fed’s transitionary Inflation scenario gets a boost
08/11ANALYST RECOMMENDATIONS : Callaway, Flutter, Qualys, Synaptics, Virgin Galactic...
08/11FUSION PHARMACEUTICALS : Wedbush Trims Price Target on Fusion Pharmaceuticals to $21 From ..
MT
08/10FUSION PHARMACEUTICALS : Corporate Presentation August 2021
PU
More news
News in other languages on FUSION PHARMACEUTICALS INC.

- No features available -

More news
Analyst Recommendations on FUSION PHARMACEUTICALS INC.
More recommendations
Chart FUSION PHARMACEUTICALS INC.
Duration : Period :
Fusion Pharmaceuticals Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends FUSION PHARMACEUTICALS INC.
Short TermMid-TermLong Term
TrendsNeutralNeutralBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 5
Last Close Price 8,56 $
Average target price 20,25 $
Spread / Average Target 137%
EPS Revisions
Managers and Directors
John Valliant Chief Executive Officer & Director
John J. Crowley Chief Financial Officer
Barbara Gayle Duncan Chairman
Eric Burak Chief Scientific Officer
James J. O'Leary Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
FUSION PHARMACEUTICALS INC.-27.15%368
GILEAD SCIENCES, INC.23.12%88 970
BIONTECH SE318.73%81 878
WUXI APPTEC CO., LTD.35.75%69 413
REGENERON PHARMACEUTICALS33.91%66 632
VERTEX PHARMACEUTICALS-21.38%48 168